Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Appropriate Titration Of Basal Insulin In Type 2 Diabetes And The Potential Role Of The Pharmacist

D. Patel, C. Triplitt, J. Trujillo
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
A substantial proportion of patients with suboptimal control of their type 2 diabetes experience delays in treatment intensification. Additionally, patients often experience overuse of basal insulin, commonly referred to as “over-basalization,” whereby basal insulin continues to be uptitrated in order to meet targets, when addition of a mealtime bolus insulin dose may be a more appropriate option. In order to overcome these challenges, there is a need to develop the capacity of allied healthcare professionals to provide appropriate support to these patients, such as during initiation or titration of basal insulin. Pharmacists play an integral role in healthcare delivery, with patients seeing their pharmacist, on average, seven times more often than their primary care physician. This places pharmacists in a unique position to provide diabetes education and care, which may help patients avoid clinical inertia. Nevertheless, the management of the disease with basal insulin is becoming increasingly complex, with growing numbers of treatment options (such as recent second-generation longer-acting basal insulin formulations) and frequently updated titration algorithms. The two most common titration schedules specify either increasing doses by a set amount every 2–3 days or a treat-to-target strategy. Neither schedule has been shown to be superior, and the decision to use one or the other should be based on a discussion between the clinician and patient after assessment of mental and physical acumen, comfort of both parties, and follow-up plans. This review article discusses basal insulin therapy options and titration algorithms from the unique perspective of the pharmacist in order to help ensure that optimal antidiabetes therapy is initiated, appropriately titrated, and maintained.Funding: Sanofi US, Inc.
This paper references
10.2337/dc12-1205
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
B. Zinman (2012)
Department of Health and Human Services Section review of 510(k)
Fda
10.1111/dme.13002
A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
S. Heller (2016)
10.2337/dc12-2329
Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes
S. Gough (2013)
10.2146/ajhp150778
Clinical pharmacist prescribing activities in the Veterans Health Administration.
Heather L Ourth (2016)
10.2337/diacare.27.2007.s15
Standards of medical care in diabetes.
H. J. Morris (2005)
Nonmedical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care
G Weeks (2016)
10.1016/S0084-3741(08)70010-6
A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes
L. Kennedy (2007)
10.1007/s13300-014-0077-8
Clinical Inertia in Individualising Care for Diabetes: Is There Time to do More in Type 2 Diabetes?
W. D. Strain (2014)
10.2337/DIABETES.53.6.1614
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
T. Heise (2004)
10.2337/DIACARE.29.04.06.DC05-0053
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.
M. Peyrot (2005)
Low-Volume Insulin Degludec 200 Units / mLOnceDaily ImprovesGlycemic ControlSimilarlytoInsulinGlargineWitha Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes A 26-week , randomized , controlled , multinational , treat-to-target trial : The BEGIN LOW VOLUME trial
Stephen (2013)
10.3121/cmr.2008.793
Insulin Analogs: Impact on Treatment Success, Satisfaction, Quality of Life, and Adherence
I. Hartman (2008)
10.1111/ijcp.12337
A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus – a systematic review and meta‐analysis
P. Ryś (2014)
10.1345/aph.1Q512
Glycemic Control and Preventive Care Measures of Indigent Diabetes Patients Within a Pharmacist-Managed Insulin Titration Program vs Standard Care
Marissa C Salvo (2012)
10.1007/s00125-012-2785-9
Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. Inzucchi (2012)
10.2337/DIACARE.29.01.06.DC05-1058
Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.
L. Kennedy (2006)
10.2337/diaspect.24.4.211
Glycemic Control in Pharmacist-Managed Insulin Titration Versus Standard Care in an Indigent Population
Jamie M Pitlick (2011)
10.2337/dc13-0331
Clinical Inertia in People With Type 2 Diabetes
K. Khunti (2013)
10.1111/j.1463-1326.2007.00756.x
Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies
T. Heise (2007)
10.2337/DIACARE.29.02.06.DC05-1989
Standards of Medical Care in Diabetes: Response to Power
V. Fonseca (2006)
10.1111/jdi.12102
Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial
Y. Onishi (2013)
10.1111/dom.12485
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
R. Ritzel (2015)
Understanding insulin management: Role of the
S. Haines (2014)
New insulin glargine 300 U/ml compared with glargine Adv Ther
GB Bolli (2015)
of Health and Human Services Section review of 510(k)
FDA. Departmen (2018)
International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes
(2014)
10.1111/j.1463-1326.2009.01060.x
Patient‐directed titration for achieving glycaemic goals using a once‐daily basal insulin analogue: an assessment of two different fasting plasma glucose targets ‐ the TITRATETM study
L. Blonde (2009)
10.1177/193229681200600229
Clinical Use of U-500 Regular Insulin: Review and Meta-Analysis
S. Reutrakul (2012)
10.1111/dom.12628
Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
I. Hadjiyianni (2016)
US prescribing information (PI)
Levemir
10.1001/jama.2017.7117
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial
C. Wysham (2017)
US prescribing information (PI). http:// products.sanofi.us/toujeo/toujeo.pdf. Accessed
Toujeo
10.3949/ccjm.83.s1.05
New insulin preparations: A primer for the clinician
L. Meneghini (2016)
10.2146/AJHP050430
Development and clinical outcomes of pharmacist-managed diabetes care clinics.
C. Morello (2006)
10.1016/S2213-8587(13)70013-5
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
B. Zinman (2013)
US prescribing information (PI)
Lantus
The treat-totarget trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
MC Riddle (2003)
10.1111/j.1463-1326.2007.00804.x
The usage of a simplified self‐titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE™ 303 study
L. Meneghini (2007)
10.4158/CS-2017-0153
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
A. Garber (2018)
10.1111/j.1463-1326.2012.01638.x
Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
T. Heise (2012)
10.1007/s12325-013-0036-1
Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)
A. Philis-Tsimikas (2013)
10.1007/s40262-014-0165-y
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
H. Haahr (2014)
10.1007/s00125-007-0911-x
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
J. Rosenstock (2007)
10.1111/dom.12438
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
G. Bolli (2015)
10.1002/14651858.CD011227.PUB2
Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care.
Greg Weeks (2016)
10.2337/DIACARE.28.5.1107
A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
J. Plank (2005)
10.1007/s00125-018-4729-5
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
M. Davies (2018)
US prescribing information (PI)
Basaglar
10.1007/s00125-019-05039-w
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
J. Buse (2019)
10.1177/1060028016663564
Effect of Clinical Pharmacist Intervention on Hemoglobin A1C Reduction in Veteran Patients With Type 2 Diabetes in a Rural Setting
J. Sullivan (2016)
10.1016/S0140-6736(98)12459-5
Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens
P. Jehle (1999)
10.1002/14651858.CD006383.pub2
Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
S. G. Swinnen (2011)
10.2147/DMSO.S54953
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
P. Thuillier (2015)
10.1111/dom.12482
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)
J. Rosenstock (2015)
10.1592/phco.26.2.248
Clinical Impact of a Pharmacist‐Managed Diabetes Mellitus Drug Therapy Management Service
Amie D. McCord (2006)
Lower withinsubject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes
T Heise (2004)
US prescribing information (PI)
Tresiba
10.1111/dom.12626
Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin
K. Khunti (2016)
10.1007/s40261-013-0096-7
A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec
S. Korsatko (2013)
10.1016/J.JCJD.2016.08.133
Safety and Efficacy of a Pragmatic Self-Titration 1 Unit/Day (INSIGHT) Algorithm for Insulin Glargine 300 U/mL (Gla-300)
L. Berard (2016)
The scope and standards for the practice of diabetes education by pharmacists
L Shane-Mcwhorter
10.2337/DIACARE.26.11.3080
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
M. Riddle (2003)
10.1016/j.jdiacomp.2015.04.003
Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study.
P. Aschner (2015)
10.2337/DIACARE.22.3.394
Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects.
R. Ollerton (1999)
A retrospective cohort study of more than 80,000 people
K. Khunti (2013)
10.2337/dc18-0559
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
J. Rosenstock (2018)
10.1016/J.CLINTHERA.2006.10.020
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.
A. Philis-Tsimikas (2006)
10.1111/j.1365-2710.2010.01218.x
Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial
E. Mehuys (2011)
10.1016/j.diabres.2010.09.023
Effect of pharmacist intervention on glycemic control in diabetes.
C. Collins (2011)
10.1111/j.1464-5491.2012.03605.x
Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study
M. Peyrot (2012)
The scope and standards for the practice of diabetes education by pharmacists. American Association of Diabetes Educators
L. Shane-McWhorter (2018)
10.1331/JAPhA.2012.11225
Implementation of a pharmacist-run telephonic insulin titration service.
Emily Weidman-Evans (2012)
10.2146/ajhp080706
Collaborative drug therapy management for initiating and adjusting insulin therapy in patients with type 2 diabetes mellitus.
Charmaine D Rochester (2010)
10.1136/bmjopen-2013-003154
Pharmacist intervention for glycaemic control in the community (the RxING study)
Yazid N. Al Hamarneh (2013)
10.1111/1753-0407.12080
Comparison of three algorithms for initiation and titration of insulin glargine in insulin‐naive patients with type 2 diabetes mellitus (既往从未使用过胰岛素的2型糖尿病患者使用三种不同的启用与滴定甘精胰岛素剂量方案的比较)
G. Dailey (2014)
10.1016/j.diabet.2017.10.001
Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
T. Bailey (2018)
10.2337/DIACARE.28.6.1282
Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine.
M. Davies (2005)
10.1002/phar.1719
Evaluation of the Impact of a Pharmacist‐Led Telehealth Clinic on Diabetes‐Related Goals of Therapy in a Veteran Population
L. G. Maxwell (2016)
10.1177/1060028017733272
Effective Interventions for Diabetes Patients by Community Pharmacists: A Meta-analysis of Pharmaceutical Care Components
M. A. Deters (2018)
10.1111/dom.12083
Once‐daily initiation of basal insulin as add‐on to metformin: a 26‐week, randomized, treat‐to‐target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes
L. Meneghini (2013)
10.1111/ijcp.12747
How much is too much? Outcomes in patients using high‐dose insulin glargine
T. Reid (2016)
10.1111/dom.12329
Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes
P. Home (2015)
10.1177/1932296815586425
Misled by the Morning “Fasting” Plasma Glucose
A. King (2015)
10.1007/s00125-005-0132-0
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study
H. Yki–Järvinen (2005)
10.2337/dc14-0006
New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1
R. Becker (2014)
Effect of clinical pharmacist intervention on A1C reduction in veteran patients with type 2 diabetes in a rural setting
J Sullivan (2016)
Expanding pharmacist provider status can improve diabetes management
L. Ide (2015)
10.1016/j.diabres.2012.10.001
Global guideline for type 2 diabetes.
F. Snoek (2014)
10.2337/dc12-2258
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010
Sarah Stark Casagrande (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar